222 related articles for article (PubMed ID: 27648688)
1. Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.
Mesher D; Soldan K; Lehtinen M; Beddows S; Brisson M; Brotherton JM; Chow EP; Cummings T; Drolet M; Fairley CK; Garland SM; Kahn JA; Kavanagh K; Markowitz L; Pollock KG; Söderlund-Strand A; Sonnenberg P; Tabrizi SN; Tanton C; Unger E; Thomas SL
Emerg Infect Dis; 2016 Oct; 22(10):1732-40. PubMed ID: 27648688
[TBL] [Abstract][Full Text] [Related]
2. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
Godi A; Bissett SL; Miller E; Beddows S
PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
[TBL] [Abstract][Full Text] [Related]
3. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.
Ahmed AI; Bissett SL; Beddows S
Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
5. Pattern of multiple human papillomavirus infection and type competition: An analysis in healthy Chinese women aged 18-45 years.
Su Y; Zheng T; Bi Z; Jia X; Li Y; Kuang X; Yang Y; Chen Q; Lin H; Huang Y; Huang S; Qiao Y; Wu T; Zhang J; Xia N
Hum Vaccin Immunother; 2024 Dec; 20(1):2334474. PubMed ID: 38619081
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of high-risk HPV and its genotypes-Implications in the choice of prophylactic HPV vaccine.
Suresh A; Suresh P; Biswas R; Rajanbabu A; Sreedhar S; Biswas L
J Med Virol; 2021 Aug; 93(8):5188-5192. PubMed ID: 33851736
[TBL] [Abstract][Full Text] [Related]
8. Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study.
Söderlund-Strand A; Uhnoo I; Dillner J
Cancer Epidemiol Biomarkers Prev; 2014 Dec; 23(12):2757-64. PubMed ID: 25380734
[TBL] [Abstract][Full Text] [Related]
9. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction.
Covert C; Ding L; Brown D; Franco EL; Bernstein DI; Kahn JA
Hum Vaccin Immunother; 2019; 15(7-8):1962-1969. PubMed ID: 30633598
[TBL] [Abstract][Full Text] [Related]
10. High-risk human papillomavirus types in HIV-infected and HIV-uninfected young women in KwaZulu-Natal, South Africa: implications for vaccination.
Mbatha JN; Taylor M; Kleppa E; Lillebo K; Galappaththi-Arachchige HN; Singh D; Kjetland EF; Baay MFD; Mkhize-Kwitshana ZL
Infect Dis (Lond); 2017 Aug; 49(8):601-608. PubMed ID: 28403727
[TBL] [Abstract][Full Text] [Related]
11. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
[TBL] [Abstract][Full Text] [Related]
12. Exploring individual HPV coinfections is essential to predict HPV-vaccination impact on genotype distribution: a model-based approach.
Pons-Salort M; Letort V; Favre M; Heard I; Dervaux B; Opatowski L; Guillemot D
Vaccine; 2013 Feb; 31(8):1238-45. PubMed ID: 23246257
[TBL] [Abstract][Full Text] [Related]
13. Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and Young Women Immunized With the Human Papillomavirus Vaccine.
Schlecht NF; Diaz A; Nucci-Sack A; Shyhalla K; Shankar V; Guillot M; Hollman D; Strickler HD; Burk RD
JAMA Netw Open; 2021 Aug; 4(8):e2121893. PubMed ID: 34424304
[TBL] [Abstract][Full Text] [Related]
14. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
Kudo R; Yamaguchi M; Sekine M; Adachi S; Ueda Y; Miyagi E; Hara M; Hanley SJB; Enomoto T
J Infect Dis; 2019 Jan; 219(3):382-390. PubMed ID: 30299519
[TBL] [Abstract][Full Text] [Related]
15. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
16. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
17. The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016.
Mesher D; Panwar K; Thomas SL; Edmundson C; Choi YH; Beddows S; Soldan K
J Infect Dis; 2018 Aug; 218(6):911-921. PubMed ID: 29917082
[TBL] [Abstract][Full Text] [Related]
18. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.
Mesher D; Panwar K; Thomas SL; Beddows S; Soldan K
BMJ Open; 2016 Feb; 6(2):e009915. PubMed ID: 26868944
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
20. Pre-vaccination prevalence of high-risk human papillomaviruses (HPV) in women from Kosovo and their related sociodemographic characteristics.
Zejnullahu Raçi P; Hošnjak L; Poljak M; Lepej SŽ; Vince A
Ginekol Pol; 2018; 89(9):485-494. PubMed ID: 30318575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
